Comparative Pharmacology
Head-to-head clinical analysis: TALWIN 50 versus ULTRAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TALWIN 50 versus ULTRAM.
TALWIN 50 vs ULTRAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Pentazocine is a mixed agonist-antagonist opioid analgesic with activity at kappa opioid receptors (agonist) and mu opioid receptors (partial agonist/antagonist). It also exhibits weak antagonistic activity at mu receptors, which reduces abuse liability but may precipitate withdrawal in opioid-dependent patients.
Tramadol is a centrally acting synthetic opioid analgesic that binds to μ-opioid receptors and inhibits norepinephrine and serotonin reuptake.
50 mg orally every 3-4 hours as needed; maximum 600 mg per day.
50-100 mg orally every 4-6 hours as needed for pain; maximum 400 mg/day (for extended-release: 100 mg once daily, titrated up to 300 mg once daily).
None Documented
None Documented
Terminal elimination half-life is 2-3 hours. In patients with hepatic impairment, half-life may extend to 5-8 hours; in renal impairment, minimal change, but active metabolite accumulation may occur.
Tramadol: ~6 hours; M1 metabolite (O-desmethyltramadol): ~7 hours; prolonged in renal/hepatic impairment
Primarily renal (60-70% as unchanged drug and conjugates), with 20-30% biliary/fecal elimination. Approximately 5-10% excreted in feces via bile.
Renal: ~90% (tramadol and metabolites; conjugated metabolites are major), Fecal: ~10%
Category C
Category C
Opioid Analgesic
Opioid Analgesic